Topline data from multiple Phase 2 studies expected throughout 2025 Q2 readout from VTX3232 study in patients with early Parkinson’s disease H2 readout from VTX2735 study in patients with recurrent pericarditis H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations... Read More